Evidence map›Paper›PMID 42713573›Full record

ArticleAdvances in laboratory medicine2026

When rare diseases do not appear as a single entity.

Isabel Solares, Estibaliz Alegre, Inmaculada Colina, Juan Jose Gavira, Beatriz Alvarez de Sierra, Sara Llorente-Gonzalez, Álvaro Gonzalez

Abstract readCase Reports
In one paragraph

Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabel SolaresRare Disease Unit, Internal Medicine Department, Clinica Universidad de Navarra, Madrid, Spain.
Estibaliz AlegreBiochemistry Department, Clínica Universidad de Navarra, Pamplona, Spain.
Inmaculada ColinaRare Disease Unit, Internal Medicine Department, Clinica Universidad de Navarra, Madrid, Spain.
Juan Jose GaviraDepartment of Cardiology, Clínica Universidad de Navarra, Pamplona, Spain.
Beatriz Alvarez de SierraDepartment of Radiology, Cancer Center, Clinica Universidad de Navarra, Madrid, Spain.
Sara Llorente-GonzalezRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, Pamplona, Spain.
Álvaro GonzalezBiochemistry Department, Clínica Universidad de Navarra, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The coexistence of multisystemic involvement in a young adult raises the need to consider rare metabolic and mitochondrial disorders. We report a case of late-onset propionic acidemia (PPA) that may have contributed to unmasking Leber hereditary optic neuropathy (LHON), an extremely infrequent association. Case presentation: A 43-year-old woman presented with acute biventricular heart failure following a viral infection. Evaluation revealed severe dilated cardiomyopathy, newly diagnosed type 2 diabetes mellitus, and bilateral sensorineural hearing loss. Genetic testing for cardiomyopathy was unremarkable. Two months later, she developed sudden bilateral blindness due to optic neuropathy. Extended genetic analysis identified a pathogenic Conclusions: In this patient, mitochondrial dysfunction from PPA may have precipitated the clinical expression of LHON, a condition with incomplete penetrance. This exceptional coexistence highlights that rare diseases may overlap and that unexplained multisystem findings warrant comprehensive metabolic and genetic evaluation.

Indexed as

Leber hereditary optic neuropathymitochondrial diseasepropionic acidemia

Identifiers

PMID42713573
PMCPMC13552808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.